Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) EVP Rong Zhou sold 1,089 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $22.00, for a total value of $23,958.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Rong Zhou also recently made the following trade(s):
- On Friday, November 9th, Rong Zhou sold 2,173 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $20.50, for a total value of $44,546.50.
NASDAQ:AMPH opened at $21.99 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.02 and a quick ratio of 1.34. Amphastar Pharmaceuticals Inc has a 1-year low of $14.40 and a 1-year high of $22.74. The firm has a market capitalization of $1.00 billion, a P/E ratio of 57.87 and a beta of 1.42.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The business had revenue of $75.54 million during the quarter, compared to analyst estimates of $76.84 million. During the same quarter last year, the company posted $0.07 EPS. Amphastar Pharmaceuticals’s revenue for the quarter was up 30.5% on a year-over-year basis. Research analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Morgan Stanley boosted its position in Amphastar Pharmaceuticals by 27.3% during the 3rd quarter. Morgan Stanley now owns 233,864 shares of the company’s stock worth $4,499,000 after acquiring an additional 50,144 shares during the period. Legal & General Group Plc boosted its position in Amphastar Pharmaceuticals by 3.6% during the 3rd quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock worth $1,425,000 after acquiring an additional 2,568 shares during the period. Nordea Investment Management AB boosted its position in Amphastar Pharmaceuticals by 37.4% during the 3rd quarter. Nordea Investment Management AB now owns 239,159 shares of the company’s stock worth $4,601,000 after acquiring an additional 65,160 shares during the period. Teachers Advisors LLC boosted its position in Amphastar Pharmaceuticals by 0.7% during the 3rd quarter. Teachers Advisors LLC now owns 566,984 shares of the company’s stock worth $10,909,000 after acquiring an additional 4,194 shares during the period. Finally, AQR Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 25.2% during the 3rd quarter. AQR Capital Management LLC now owns 24,626 shares of the company’s stock worth $474,000 after acquiring an additional 4,963 shares during the period. Institutional investors and hedge funds own 44.74% of the company’s stock.
AMPH has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. BidaskClub upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a research report on Wednesday, November 14th. Needham & Company LLC set a $25.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 9th. Finally, ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Amphastar Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.60.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
See Also: Float
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.